Sel-1L Antibody (G-11): sc-377351

Sel-1L Antibody (G-11) is a mouse monoclonal IgG2b antibody that detects Sel-1L in mouse, rat, and human samples through various applications including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), and enzyme-linked immunosorbent assay (ELISA). Sel-1L is primarily located in the cytoplasm and nuclei of normal pancreatic cells, where Sel-1L plays a crucial role in regulating cellular proliferation and maintaining tissue homeostasis. Sel-1L (G-11) antibody′s antiproliferative properties are particularly significant as Sel-1L inhibits tumor cell growth in various cancers, including breast, pancreatic, esophageal, and prostate cancers. By remodeling the extracellular matrix, Sel-1L creates a microenvironment that is less conducive to invasive growth, thereby potentially preventing tumor progression. Notably, Sel-1L expression is drastically downregulated or absent in approximately two-thirds of breast tumors, leading to disrupted cell-matrix interactions and impaired collagen binding. This disruption may facilitate the transition from normal mucosa to neoplastic lesions, indicating that Sel-1L could serve as a valuable biomarker for identifying patients at high risk of developing cancer. With a multifaceted role in tumor biology and cellular signaling, anti-Sel-1L antibody (G-11) is an essential tool for researchers investigating cancer mechanisms and therapeutic targets.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

Sel-1L Antibody (G-11) References:

1. SEL1L a multifaceted protein playing a role in tumor progression.  |  Biunno, I., et al. 2006. J Cell Physiol. 208: 23-38. PMID: 16331677
2. SEL1L plays a major role in human malignant gliomas.  |  Mellai, M., et al. 2020. J Pathol Clin Res. 6: 17-29. PMID: 31111685
3. SEL1L-HRD1 ER-associated degradation suppresses hepatocyte hyperproliferation and liver cancer.  |  Bhattacharya, A., et al. 2022. iScience. 25: 105183. PMID: 36238898
4. Hepatic SEL1L-HRD1 ER-associated degradation regulates systemic iron homeostasis via ceruloplasmin.  |  Thepsuwan, P., et al. 2023. Proc Natl Acad Sci U S A. 120: e2212644120. PMID: 36595688
5. Hypomorphic variants of SEL1L-HRD1 ER-associated degradation are associated with neurodevelopmental disorders.  |  Wang, HH., et al. 2024. J Clin Invest. 134: PMID: 37943610
6. Hypomorphic human SEL1L and HRD1 variants uncouple multilayered ER-associated degradation machinery.  |  Umphred-Wilson, K. and Adoro, S. 2024. J Clin Invest. 134: PMID: 38226624
7. Proteomic screens of SEL1L-HRD1 ER-associated degradation substrates reveal its role in glycosylphosphatidylinositol-anchored protein biogenesis.  |  Wei, X., et al. 2024. Nat Commun. 15: 659. PMID: 38253565
8. Regulation of leptin signaling and diet-induced obesity by SEL1L-HRD1 ER-associated degradation in POMC expressing neurons.  |  Mao, H., et al. 2024. Nat Commun. 15: 8435. PMID: 39343970
9. Purkinje cell-specific deficiency in SEL1L-hrd1 endoplasmic reticulum-associated degradation causes progressive cerebellar ataxia in mice.  |  Torres, M., et al. 2024. JCI Insight. 9: PMID: 39352758
10. Role of SEL1L in the progression of solid tumors, with a special focus on its recent therapeutic potential.  |  Darmadi, D., et al. 2025. Cell Biol Int. 49: 16-32. PMID: 39364680

The preferred Sel-1L antibody is Sel-1L Antibody (F-3): sc-377350.